Given the prominent role that inflammation is known to play in progression of kidney disease in the setting of diabetes as well as in other kidney diseases that respond favorably to SGLT2 inhibitors (18, 25, 26), we performed additional studies to validate transcriptomic changes related to the NF-κB pathway. This evidence concerns the gene NFKB1 and kidney disorder.